BACKGROUND: Helper-dependent (HD) adenovirus (Ad) vectors, deleted of all viral coding sequences, have a higher cloning capacity, improved performance of tissue-specific promoters, and reduced toxicity in animals relative to first-generation Ad vectors, making these vectors promising tools for gene transfer in vitro and in vivo. However, the large size of HDAd precursor plasmids renders them relatively difficult to manipulate due to the paucity of unique restriction enzyme sites suitable for transgene insertion and to the size constraints imposed by the viral packaging machinery. METHODS: We have constructed a series of HDAd precursor plasmids that allows cassette insertion at a unique site in the vector backbone. We have tested whether these vector backbones will support the tissue-specificity of inserted expression cassettes in a study of the activity of the potentially breast-cancer-specific mammaglobin promoter and enhancer. RESULTS: We report here the generation of a series of HDAd precursor plasmids, both with and without an additional reporter expression cassette, that were designed to accommodate a wide range in size of inserted DNA. The system was validated for transcriptional targeting studies by demonstrating the tissue-specificity and activity of the mammaglobin promoter rescued using this precursor system. In addition, we have extended our previous studies on the mammaglobin promoter by demonstrating that two copies of the mammaglobin enhancer fused to the minimal promoter surpassed the activity of the single enhancer/promoter by at least 10-fold in breast cancer cells while maintaining only minimal expression in normal cells both in vitro and in a mouse tumor model. CONCLUSIONS: This versatile plasmid system simplifies the construction of HDAd vectors and was valuable in demonstrating the targeting potential of the mammaglobin promoter for breast cancer gene therapy. Copyright 2006 John Wiley & Sons, Ltd.
BACKGROUND: Helper-dependent (HD) adenovirus (Ad) vectors, deleted of all viral coding sequences, have a higher cloning capacity, improved performance of tissue-specific promoters, and reduced toxicity in animals relative to first-generation Ad vectors, making these vectors promising tools for gene transfer in vitro and in vivo. However, the large size of HDAd precursor plasmids renders them relatively difficult to manipulate due to the paucity of unique restriction enzyme sites suitable for transgene insertion and to the size constraints imposed by the viral packaging machinery. METHODS: We have constructed a series of HDAd precursor plasmids that allows cassette insertion at a unique site in the vector backbone. We have tested whether these vector backbones will support the tissue-specificity of inserted expression cassettes in a study of the activity of the potentially breast-cancer-specific mammaglobin promoter and enhancer. RESULTS: We report here the generation of a series of HDAd precursor plasmids, both with and without an additional reporter expression cassette, that were designed to accommodate a wide range in size of inserted DNA. The system was validated for transcriptional targeting studies by demonstrating the tissue-specificity and activity of the mammaglobin promoter rescued using this precursor system. In addition, we have extended our previous studies on the mammaglobin promoter by demonstrating that two copies of the mammaglobin enhancer fused to the minimal promoter surpassed the activity of the single enhancer/promoter by at least 10-fold in breast cancer cells while maintaining only minimal expression in normal cells both in vitro and in a mousetumor model. CONCLUSIONS: This versatile plasmid system simplifies the construction of HDAd vectors and was valuable in demonstrating the targeting potential of the mammaglobin promoter for breast cancer gene therapy. Copyright 2006 John Wiley & Sons, Ltd.
Authors: Lorenz Jager; Martin A Hausl; Christina Rauschhuber; Nicola M Wolf; Mark A Kay; Anja Ehrhardt Journal: Nat Protoc Date: 2009 Impact factor: 13.491
Authors: Cynthia M Pruss; Mia Golder; Andrea Bryant; Carol A Hegadorn; Erin Burnett; Kimberly Laverty; Kate Sponagle; Aly Dhala; Colleen Notley; Sandra Haberichter; David Lillicrap Journal: Blood Date: 2011-02-23 Impact factor: 22.113
Authors: S Chaurasiya; P Hew; P Crosley; D Sharon; K Potts; K Agopsowicz; M Long; C Shi; M M Hitt Journal: Cancer Gene Ther Date: 2016-05-06 Impact factor: 5.987
Authors: Maha Othman; Yvette Chirinian; Christine Brown; Colleen Notley; Nicholas Hickson; Daniel Hampshire; Suzanne Buckley; Simon Waddington; Alan L Parker; Andrew Baker; Paula James; David Lillicrap Journal: Blood Date: 2010-08-09 Impact factor: 22.113
Authors: Yasuaki Shida; Natalia Rydz; David Stegner; Christine Brown; Jeffrey Mewburn; Kate Sponagle; Ozge Danisment; Bredon Crawford; Barbara Vidal; Carol A Hegadorn; Cynthia M Pruss; Bernhard Nieswandt; David Lillicrap Journal: Blood Date: 2014-07-22 Impact factor: 22.113
Authors: Rodger E Tiedemann; Xinliang Mao; Chang-Xin Shi; Yuan Xiao Zhu; Stephen E Palmer; Michael Sebag; Ron Marler; Marta Chesi; Rafael Fonseca; P Leif Bergsagel; Aaron D Schimmer; A Keith Stewart Journal: J Clin Invest Date: 2008-05 Impact factor: 14.808
Authors: Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel Journal: Cancer Cell Date: 2007-08 Impact factor: 31.743